



Presbia PLC  
Investor Relations Department  
8845 Irvine Center Drive, Suite  
100  
Irvine, CA 92618  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: LENS

Last Trade:	4.61
Trade Time:	3:59 PM ET Oct 13, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	1.86 - 5.88
Volume	190

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

We are an ophthalmic device company that has developed and is currently marketing a proprietary optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. Our lens, the Presbia Flexivue Microlens™, is a miniature lens designed to be surgically implanted in a patient's eye to improve that patient's ability to see objects at close distances. Our current strategy is to continue to commercialize the Presbia Flexivue Microlens™ in certain strategic countries where we currently have marketing approval and t... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

*Oct 2, 2017*  
[Presbia to Participate in the XXXV Congress of the European Society of Cataract & Refractive Surgeons and in the International Society of Presbyopia 2017](#)

*Sep 7, 2017*  
[Presbia to Participate in Rodman & Renshaw 19th Annual Global Investment Conference](#)

*May 31, 2017*  
[May 31, 2017 8-K Current Report](#)

*May 30, 2017*  
[Presbia to Participate in Jefferies 2017 Global Healthcare Conference](#)

*May 23, 2017*  
[May 23, 2017 8-K Current Report](#)

### Upcoming Events [\[ View all \]](#)

*Nov 11–14, 2017*  
[American Academy of Ophthalmology \(AAO\)](#)

### Financials [\[ View all \]](#)

[Second Quarter Financial Results](#)

*Mar 29, 2017*  
[Annual Report \(10-K\)](#)

*Jun 27, 2017*  
[Proxy Statement \(DEF 14A\)](#)

*Aug 11, 2017*  
[Quarterly Report \(10-Q\)](#)

*May 12, 2017*  
[Quarterly Report \(10-Q\)](#)

*Nov 4, 2016*  
[Quarterly Report \(10-Q\)](#)